• Sun. Nov 27th, 2022

General

  • Home
  • Channel Advisor (ECOM) – It Wasn’t Pelosi: A Congress Member Bought Up To $250K In Stock Days Ahead Of Company’s Sale, Pocketing Thousands

Channel Advisor (ECOM) – It Wasn’t Pelosi: A Congress Member Bought Up To $250K In Stock Days Ahead Of Company’s Sale, Pocketing Thousands

Good timing, lucky buy, or more to the story? Those are the choices the public will likely be attributing to a large purchase of shares of a commerce company by…

Canadian Solar (CSIQ), (ENPH) – As European Energy Bills Soar, Demand Is Rising In This Sector: 6 Stock Ideas

Inflation jumped to a new all-time high of 8.9% in July, sparking a cost-of-living crisis in Europe for the 19 countries bound by the euro, fueled by rising energy costs.…

GOP Senator Wants Marijuana Legalization On Ballot, Doctors Can’t Discriminate Against Pot Users & More Cannabis Updates

GOP Minnesota Senator Wants To Put Rec Marijuana Legalization On Ballot Former GOP state senator Scott Jensen and gubernatorial nominee said the state should decriminalize “trivial amounts” of marijuana and wipe out prior…

Novak Djokovic And Hedge Funder Bill Ackman Join Forces: Will This Upstart Be The ‘LIV Golf’ For Tennis?

Bill Ackman, the CEO of Pershing Square Capital, and Ahmad Nassar, CEO of the Professional Tennis Players Association appeared on CNBC’s ‘Squawk Box,’ to discuss the billionaire’s new investment in the…

Astrazeneca Plc (AZN), ASTRAZENECA PLC O (AZNCF) – AstraZeneca Imfinzi Combo Scores FDA Approval As First Immunotherapy Regimen For Biliary Tract Cancer

The FDA approved AstraZeneca plc’s AZN Imfinzi (durvalumab) for locally advanced or metastatic biliary tract cancer (BTC) in combination with chemotherapy (gemcitabine plus cisplatin). The approval was based on the results…